← All trials
NCT06761651
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2023
- Primary completion
- Jan 1, 2026
- Completion date
- Oct 15, 2026
- First posted
- Jan 7, 2025
- Last posted
- Jan 16, 2025
- Enrollment
- 50
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tavotek BiotherapeuticsLead sponsor
- Henan Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.